Reviewing Coherus BioSciences Inc. (CHRS)’s and Gemphire Therapeutics Inc. (NASDAQ:GEMP)’s results

As Biotechnology businesses, Coherus BioSciences Inc. (NASDAQ:CHRS) and Gemphire Therapeutics Inc. (NASDAQ:GEMP), are affected by contrast. This especially applies to their dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Coherus BioSciences Inc. 18 11.69 N/A -2.66 0.00
Gemphire Therapeutics Inc. 1 0.00 N/A -1.42 0.00

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of Coherus BioSciences Inc. and Gemphire Therapeutics Inc.

Profitability

Table 2 represents Coherus BioSciences Inc. (NASDAQ:CHRS) and Gemphire Therapeutics Inc. (NASDAQ:GEMP)’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Coherus BioSciences Inc. 0.00% 0% -120.3%
Gemphire Therapeutics Inc. 0.00% -212.1% -101.7%

Liquidity

3.8 and 3.8 are the respective Current Ratio and a Quick Ratio of Coherus BioSciences Inc. Its rival Gemphire Therapeutics Inc.’s Current and Quick Ratios are 3.6 and 3.6 respectively. Coherus BioSciences Inc. has a better chance of clearing its pay short and long-term debts than Gemphire Therapeutics Inc.

Analyst Recommendations

Recommendations and Ratings for Coherus BioSciences Inc. and Gemphire Therapeutics Inc. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Coherus BioSciences Inc. 0 0 3 3.00
Gemphire Therapeutics Inc. 0 0 0 0.00

$33.67 is Coherus BioSciences Inc.’s consensus price target while its potential upside is 66.68%.

Institutional and Insider Ownership

Institutional investors held 97.45% of Coherus BioSciences Inc. shares and 23.6% of Gemphire Therapeutics Inc. shares. Coherus BioSciences Inc.’s share held by insiders are 0.3%. Comparatively, Gemphire Therapeutics Inc. has 28.34% of it’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Coherus BioSciences Inc. -5.51% -25.31% 5.45% 28.69% -6.56% 85.86%
Gemphire Therapeutics Inc. -12.35% -21.74% -49.1% -36.25% -91.55% -22.08%

For the past year Coherus BioSciences Inc. has 85.86% stronger performance while Gemphire Therapeutics Inc. has -22.08% weaker performance.

Summary

Coherus BioSciences Inc. beats on 6 of the 8 factors Gemphire Therapeutics Inc.

Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The company’s product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, non–small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. Its product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Behçet's Disease, Crohn’s Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular (wet) age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Coherus Biosciences, Inc. has license agreement with Daiichi Sankyo Company, Limited; Baxalta Incorporated, Baxalta US Inc., and Baxalta GmbH; Genentech, Inc.; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia cardiovascular disease and nonalcoholic fatty liver disease/non-alcoholic steatohepatitis (NASH). It is developing gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy and for those patients who present with NASH. The company is headquartered in Livonia, Michigan.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.